...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Transplant infectious disease: an official journal of the Transplantation Society >Valganciclovir ( VGCV VGCV ) followed by cytomegalovirus ( CMV CMV ) hyperimmune globulin compared to VGCV VGCV for 200?days in abdominal organ transplant recipients at high risk for CMV CMV infection: A prospective, randomized pilot study
【24h】

Valganciclovir ( VGCV VGCV ) followed by cytomegalovirus ( CMV CMV ) hyperimmune globulin compared to VGCV VGCV for 200?days in abdominal organ transplant recipients at high risk for CMV CMV infection: A prospective, randomized pilot study

机译：Valganciclovir（VGCV VGCV）随后是CytomeGalovirus（CMV CMV）超极化球蛋白与VGCV VGCV相比，在腹部器官移植受者的高风险中的腹腔器vGCV与CMV CMV感染的高风险：一项前瞻性，随机试点研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background With the advent of effective antivirals against cytomegalovirus ( CMV ), use of CMV hyperimmune globulin (HIG) has decreased. Although antiviral prophylaxis in patients at high risk for CMV is effective, many patients still have late infection, never developing antibodies sufficient to achieve immunity. Utilizing a combination of antiviral and CMV HIG may allow patients to achieve immunity and decrease late CMV infections. Methods This was a prospective randomized, open‐label, pilot study comparing valganciclovir ( VGCV ) prophylaxis for 200?days vs VGCV for 100?days followed by CMV HIG in abdominal transplant recipients at high risk for CMV . The primary outcome was a comparison of late CMV disease. Results Forty patients were randomized to VGCV for 200?days (n?=?20) or VGCV for 100?days followed by 3 doses of monthly CMV HIG (n?=?20). Numerically, more overall CMV infections occurred in the CMV HIG group (45 vs 20%, P ?=?.09). No differences in overall CMV infections or late CMV disease were seen between groups (20% vs 15%, P ?=?1.00 and 0 vs 0, P ?=?1.00). All CMV disease occurred within 200?days, with 63% occurring while patients were on VGCV . No differences were found in toxicities, graft function, or rejection between groups. Patients with CMV infection at any time had a higher body weight than those who did not have an infection (82 vs 95?kg, P ?=?.049). Conclusion Use of CMV HIG sequentially with prophylaxis may be an effective and affordable prophylactic regimen in abdominal transplant recipients at high risk for CMV , and warrants larger prospective study. Increased monitoring for patients with obesity may be warranted.
机译：摘要背景随着对缩细胞病毒（CMV）的有效抗病毒体的出现，使用CMV超微割球蛋白（HIG）的使用减少了。虽然CMV风险高风险的抗病毒预防是有效的，但许多患者仍有晚期感染，从未开发足以达到免疫的抗体。利用抗病毒和CMV HIG的组合可以让患者达到免疫并降低晚期CMV感染。方法这是一个预期的随机开放标签，试验研究比较200？天对VGCV的Valganciclovir（VGCV）预防100？天在腹移植受者中的CMV HIG以高风险CMV。主要结果是晚期CMV病的比较。结果将40例患者随机分配到VGCV 200？天（n？=Δ20）或vgcv 100？天，后跟3剂每月CMV hig（n？=？20）。在数值上，CMV HIG组发生更多的总体CMV感染（45 Vs 20％，P？= 09）。在基团之间看到总体CMV感染或晚期CMV疾病的差异（20％与15％，p？= 1.00和0 Vs 0，p？= 1.00）。所有CMV病发生在200？天内，患者在VGCV上发生63％。在毒性，移植物功能或组之间拒绝没有差异。随时对CMV感染的患者具有比没有感染的人更高的体重（82 Vs 95？kg，p？= 049）。结论依次使用预防性的CMV HIG可能是腹移植受者的有效且价格实惠的预防性方案，其高风险CMV，并担保前瞻性研究。可能需要增加对肥胖患者的监测。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号